Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Tumor Suppressor Genes of Bladder Cancer and Potential for Gene Therapy

  • Chapter
Bladder Disease, Part A

  • 302 Accesses

Abstract

Each year, more than 50,000 new cases of bladder cancer are diagnosed.27 Superficial bladder cancers constitute 80% of these neoplasms and are associated with a high rate of tumor recurrence despite treatment consisting of transurethral resection and intravesical chemotherapy or immunotherapy.28 Tumor progression within 5 years occurs in 30 to 40% of patients with high-risk superficial disease; 15 to 34% of patients with superficial bladder cancer die from it.10,23 The prognosis for patients with advanced tumors is poor, even for patients who receive aggressive multimodal therapy. Only 20 to 40% of patients with advanced bladder cancer survive 5 years.10,23 Thus, novel treatments are needed to improve the prognosis for patients with bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aveyard JS, Skilleter A, Habuchi T, Knowles MA: Somatic mutation of PTEN in bladder carcinoma. Br J Cancer, 80:904, 1999.

    Article  PubMed  CAS  Google Scholar 

  2. Barbra AD, Hardin J, Ray J, Gage FH: Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg, 79:729, 1993.

    Article  Google Scholar 

  3. Bennett MV, Barrio LC, Bargiello TA, Spray DC, Hertzberg E, Saez JC: Gap junctions: new tools, new answers, new questions. Neuron, 6:305, 1991.

    Article  PubMed  CAS  Google Scholar 

  4. Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russell S, et al: Vectors in cancer therapy: how will they deliver? Cancer Gene Ther, 2:291, 1995.

    PubMed  CAS  Google Scholar 

  5. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res, 57:4997, 1997.

    PubMed  CAS  Google Scholar 

  6. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al: Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 16:3215, 1998.

    Article  PubMed  CAS  Google Scholar 

  7. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F: Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene, 14:3059, 1997.

    Article  PubMed  CAS  Google Scholar 

  8. Carystinos GD, Katabi MM, Laird DW, Galipeau J, Chan H, Alaoui-Jamali MA, et al: Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. Clin Cancer Res, 5:61, 1999.

    PubMed  CAS  Google Scholar 

  9. Cirenei N, Colombo BM, Mesnil M, Benedetti S, Yamasaki H, Finocchiaro G: In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas: consequences for HSVtk/GCV anticancer gene therapy. Gene Ther, 5:1221, 1998.

    Article  PubMed  CAS  Google Scholar 

  10. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol, 158:62, 1997.

    Article  PubMed  CAS  Google Scholar 

  11. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 256:1550, 1992.

    Article  PubMed  CAS  Google Scholar 

  12. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, et al: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res, 57:4710, 1997.

    PubMed  CAS  Google Scholar 

  13. Dermietzel R, Spray DC: Gap junctions in the brain: where, what type, how many and why? Trends Neurosci, 16:186, 1993.

    Article  PubMed  CAS  Google Scholar 

  14. Duflot-Dancer A, Piccoli C, Rolland A, Yamasaki H, Mesnil M: Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther, 5:1372, 1998.

    Article  PubMed  CAS  Google Scholar 

  15. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res, 55:5151, 1995.

    PubMed  CAS  Google Scholar 

  16. Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC: Involvement of gap junctions in tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA, 89:10218, 1991.

    Google Scholar 

  17. Estin D, Li M, Spray D, Wu JK: Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery, 44:361, 1999.

    Article  PubMed  CAS  Google Scholar 

  18. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al: The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res, 53:5274, 1993.

    PubMed  CAS  Google Scholar 

  19. Ghoumari AM, Mouawad R, Zerrouqi A, Nizard C, Provost N, Khayat D, et al: Actions of HSVtk and connexin43 gene delivery on gap junctional communication and drug sensitization in hepatocellular carcinoma. Gene Ther, 5:1114, 1998.

    Article  PubMed  CAS  Google Scholar 

  20. Grossman HB, Liebert M, Lee IK, Lee SW: Decreased connexin expression and intercellular communication in human bladder cancer cells. Cancer Res, 54:3062, 1994.

    PubMed  CAS  Google Scholar 

  21. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res, 57:3660, 1997.

    PubMed  CAS  Google Scholar 

  22. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, et al: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther, 3:121,1996.

    PubMed  CAS  Google Scholar 

  23. Herr HW: Natural history of superficial bladder tumors: 10-to 20-year follow-up of treated patients. World J Urol, 15:84, 1997.

    Article  PubMed  CAS  Google Scholar 

  24. Hirschi KK, Xu CE, Tsukamoto T, Sager R: Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary cells and restore differentiation potential. Cell Growth Differ, 7:861, 1996.

    PubMed  CAS  Google Scholar 

  25. Kim SK, Su LK, Oh Y, Kemp BL, Hong WK, Mao L: Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene, 16:89, 1998.

    Article  PubMed  CAS  Google Scholar 

  26. Knuechel R, Siebert-Wellnhofer A, Traub O, Dermietzel R: Connexin expression and intercellular communication in two-and three-dimensional in vitro cultures of human bladder carcinoma. Am J Pathol, 149:1321, 1996.

    PubMed  CAS  Google Scholar 

  27. Kozlowski J: Immunotherapy of bladder cancer. J Urol, 162:1581, 1999.

    Article  PubMed  CAS  Google Scholar 

  28. Kroft SH, Oyasu R: Biology of disease. Urinary bladder cancer: mechanisms of development and progression. Lab Invest, 71:158, 1994.

    PubMed  CAS  Google Scholar 

  29. Lee SW, Tomasetto, JC, Paul DL, Sager R: Transcriptional down-regulation of gap junction proteins blocks junctional communication in mammary cell lines. J Cell Biol, 118:1213, 1992.

    Article  PubMed  CAS  Google Scholar 

  30. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275:1943, 1997.

    Article  CAS  Google Scholar 

  31. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet, 16:64, 1997.

    Article  PubMed  CAS  Google Scholar 

  32. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al: Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet, 16:333, 1997.

    Article  PubMed  CAS  Google Scholar 

  33. McMasters RA, Saylors RL, Jones KE, Hendrix ME, Moyer MP, Drake RR: Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. Hum Gene Ther, 9:2253, 1998.

    Article  PubMed  CAS  Google Scholar 

  34. Mesnil M, Krutovskikh V, Piccoli C, Elfgang C, Traub O, Willecke K, et al: Negative growth control of HeLa cells by connexin gene: connexin species specificity. Cancer Res, 55:629, 1995.

    PubMed  CAS  Google Scholar 

  35. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA, 93:1831, 1996.

    Article  PubMed  CAS  Google Scholar 

  36. Mesnil M, Piccoli C, Yamasaki H: A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res, 57:2929, 1997.

    PubMed  CAS  Google Scholar 

  37. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res, 46:5276, 1986.

    PubMed  CAS  Google Scholar 

  38. Moolten FL, Wells JM, Heyman RA, Evans RM: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther, 1:125, 1990.

    Article  PubMed  CAS  Google Scholar 

  39. Naus CC, Bechberger JF, Caveney S, Wilson JX: Expression of gap junction genes in astrocytes and C6 glioma cells. Neurosci Lett, 126:33, 1991.

    Article  PubMed  CAS  Google Scholar 

  40. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, et al: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet, 6:1383, 1997.

    Article  PubMed  CAS  Google Scholar 

  41. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res, 57:3657, 1997.

    PubMed  CAS  Google Scholar 

  42. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med, 2 985, 1996.

    Article  PubMed  CAS  Google Scholar 

  43. Sandberg AA, Berger CS: Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol, 151:545, 1994.

    PubMed  CAS  Google Scholar 

  44. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res, 59:1820, 1999.

    PubMed  CAS  Google Scholar 

  45. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res, 54:784, 1994.

    PubMed  CAS  Google Scholar 

  46. Starink TM, van der Veen JP, Arwert, F, de Waal LP, de Lange GG, Gille JJ, et al: The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet, 29:222, 1986.

    Article  PubMed  CAS  Google Scholar 

  47. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15:356, 1997.

    Article  PubMed  CAS  Google Scholar 

  48. Tanaka M, Müllauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, et al: Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res, 55:3228, 1995.

    PubMed  CAS  Google Scholar 

  49. Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T, et al: Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice. Cancer Gene Ther, 6:482, 1999.

    Article  PubMed  CAS  Google Scholar 

  50. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al:. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 57:3935, 1997.

    PubMed  CAS  Google Scholar 

  51. Vet JA, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FM, Schalken JA: Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab. Invest, 73:837, 1995.

    PubMed  CAS  Google Scholar 

  52. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC: The bystander effect by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther, 4:577, 1997.

    Article  PubMed  CAS  Google Scholar 

  53. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res, 57:4183, 1997.

    PubMed  CAS  Google Scholar 

  54. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A: Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol, 155:753, 1996.

    Article  PubMed  CAS  Google Scholar 

  55. Yang L, Chiang Y, Lenz HJ, Danenberg KD, Spears CP, Gordon EM, et al: Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther, 9:719, 1998.

    Article  PubMed  CAS  Google Scholar 

  56. Zhu D, Kidder GM, Caveney S, Naus CC: Growth retardation in glioma cells cocultured with cells overexpressing a gap junction protein. Proc Natl Acad Sci USA, 89:10218, 1992.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology M. D. Anderson Cancer Center, The University of Texas, Texas, USA

    Motoyoshi Tanaka & H. Barton Grossman

Authors
  1. Motoyoshi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Barton Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Children’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

    Anthony Atala

  2. Ridgefield, Connecticut, USA

    Debra Slade

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tanaka, M., Grossman, H.B. (2003). Tumor Suppressor Genes of Bladder Cancer and Potential for Gene Therapy. In: Atala, A., Slade, D. (eds) Bladder Disease, Part A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8889-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-8889-8_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4707-1

  • Online ISBN: 978-1-4419-8889-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation